AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Publication|Articles|November 20, 2024
- November 2024
- Volume 30
- Issue 12
- Pages: SP952-SP956
As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?
Author(s)Ryan Flinn, Mary Caffrey
Advertisement
Advertisement
The recent FDA approval in multiple myeloma of isatuximab (Sarclisa; Sanofi) marked a significant advance for patients newly diagnosed with the disease. When added to the triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd), the combination reduced the risk of disease progression and death by 40% compared with the VRd triplet alone for patients who cannot receive a transplant.1
Related to this article
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Advertisement
Advertisement